Postnatal steroids to prevent bronchopulmonary dysplasia in high-risk preterm infants
Bronchopulmonary dysplasia (BPD) is diagnosed in approximately 40% of extremely preterm infants, those born before 28 weeks’ gestational age, and affects roughly 10,000 to 15,000 infants annually in the United States alone. Current treatment of BPD aims to not only aid in the survival of the infant...
Main Author: | O'Day, Emily |
---|---|
Other Authors: | Levesque, Bernadette |
Language: | en_US |
Published: |
2019
|
Subjects: | |
Online Access: | https://hdl.handle.net/2144/38680 |
Similar Items
-
Analysis of status of preterm infants with bronchopulmonary dysplasia
by: Chernenkov Yu.V., et al.
Published: (2017-06-01) -
Increased Regulatory T Cells Precede the Development of Bronchopulmonary Dysplasia in Preterm Infants
by: Julia Pagel, et al.
Published: (2020-09-01) -
Evaluating the use of corticosteroids in preventing and treating bronchopulmonary dysplasia in preterm neonates
by: Olaloko O, et al.
Published: (2018-07-01) -
Predicting Long-Term Respiratory Outcomes in Premature Infants: Is It Time to Move beyond Bronchopulmonary Dysplasia?
by: Deepak Jain, et al.
Published: (2020-12-01) -
Phenotypes of Bronchopulmonary Dysplasia
by: Shih-Hsin Wang, et al.
Published: (2020-08-01)